[{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Reveals Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome Did Not Meet Primary Endpoint","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Presents New Long-Term AUSTEDO\u00ae (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"PainReform","sponsor":"Lotus Clinical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trialof PRF-110 in Patients Undergoing Bunionectomy Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"PainReform"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mapi Pharma to Present Posters on GA Depot for Treating Relapsing Forms of Multiple Sclerosis (MS) and Primary Progressive Forms of Multiple Sclerosis at the American Academy of Neurology (AAN) 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Mapi Pharma"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm (MIP) for P2B001 in South Korea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharma Two B"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharma Two B to Host a Virtual KOL Event on Successful Phase III Study Results of P2B001 in Parkinson\u2019s Disease (PD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharma Two B"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharma Two B"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharma Two B Presents Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at the MDS International Congress of Parkinson's Disease and Movement Disorders\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharma Two B"},{"orgOrder":0,"company":"NeuroDerm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyoND Phase 2b Data Indicates ND0612 Has a Positive Long-Term Safety Profile for People with Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NeuroDerm"},{"orgOrder":0,"company":"NeuroDerm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"NeuroDerm"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
PRF-110 (ropivacaine) is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended postoperative analgesia.
ND0612 is a continuous, subcutaneous infusion levodopa/carbidopa delivery system under development for patients with Parkinson's disease (PD) and motor fluctuations.
P2B001 showed superior efficacy to each of its individual components in the trial and comparable efficacy to marketed doses of Pramipexole ER, but with reduced adverse events related to dopaminergic side effects and sleepiness, and with less worsening on the ESS.
AUSTEDO (deutetrabenazine) safety findings were consistent with findings from the overall OLE study population (n=337), with no new safety concerns from long-term treatment.
AUSTEDO (deutetrabenazine) Tablets,is first and only vesicular monoamine transporter 2 inhibitor approved by U.S. Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.
Results demonstrated that P2B001, a combination of dopamine agonist, pramipexole, and MAO-B inhibitor, rasagiline has symptomatic benefits comparable to higher doses of marketed pramipexole ER, yet with less dopaminergic side effects and significantly less daytime sleepiness.
Long-term safety data from the Phase 2b BeyoND study demonstrated a positive ND0612, an investigational drug-device combination safety and tolerability profile beyond one year in people with Parkinson's disease.
At AAN, company will be presenting 5 year data from Phase IIa study in RRMS. Also, the results seeN in the ongoing Phase II study for GA Depot in primary progressive MS (PPMS) patients, to be presented at the meeting as plan to initiate a Phase-3 for PPMS at the end of 2022.
Results demonstrate P2B001 (pramipexole) distinctive combination of efficacy and enhanced safety, supporting its potential as a first-line treatment option for people with early PD.
Under the terms of the agreement, Myung In Pharm will seek regulatory approval for P2B001 in South Korea and will manufacture, commercialize and distribute P2B001 in the region.